{"id":584,"date":"2022-02-14T18:42:25","date_gmt":"2022-02-14T18:42:25","guid":{"rendered":"https:\/\/www.socra.org\/blog\/?p=584"},"modified":"2022-10-04T16:06:14","modified_gmt":"2022-10-04T16:06:14","slug":"research-recruitment-study-mychart-message-recruitment","status":"publish","type":"post","link":"https:\/\/www.socra.org\/blog\/research-recruitment-study-mychart-message-recruitment\/","title":{"rendered":"Research Recruitment Study \u2013 MyChart Message Recruitment"},"content":{"rendered":"\n<div class=\"wp-block-media-text alignwide is-stacked-on-mobile is-image-fill\" style=\"grid-template-columns:28% auto\"><figure class=\"wp-block-media-text__media\" style=\"background-image:url(https:\/\/www.socra.org\/blog\/wp-content\/uploads\/2022\/02\/Snyder-Andrew-683x1024.jpg);background-position:52% 0%\"><img decoding=\"async\" loading=\"lazy\" width=\"683\" height=\"1024\" src=\"https:\/\/www.socra.org\/blog\/wp-content\/uploads\/2022\/02\/Snyder-Andrew-683x1024.jpg\" alt=\"\" class=\"wp-image-586 size-full\" srcset=\"https:\/\/www.socra.org\/blog\/wp-content\/uploads\/2022\/02\/Snyder-Andrew-683x1024.jpg 683w, https:\/\/www.socra.org\/blog\/wp-content\/uploads\/2022\/02\/Snyder-Andrew-200x300.jpg 200w, https:\/\/www.socra.org\/blog\/wp-content\/uploads\/2022\/02\/Snyder-Andrew-768x1152.jpg 768w, https:\/\/www.socra.org\/blog\/wp-content\/uploads\/2022\/02\/Snyder-Andrew-1024x1536.jpg 1024w, https:\/\/www.socra.org\/blog\/wp-content\/uploads\/2022\/02\/Snyder-Andrew-1365x2048.jpg 1365w, https:\/\/www.socra.org\/blog\/wp-content\/uploads\/2022\/02\/Snyder-Andrew-scaled.jpg 1707w\" sizes=\"(max-width: 683px) 100vw, 683px\" \/><\/figure><div class=\"wp-block-media-text__content\">\n<h2 style=\"font-size:29px\">Andrew Snyder MBA, PMP, FACMPE<\/h2>\n<\/div><\/div>\n\n\n\n<p>One of the most common challenges of conducting <a href=\"https:\/\/www.socra.org\/membership\/volunteer-get-involved\/\">clinical trials<\/a> is related to problems with recruitment.&nbsp;&nbsp; Insufficient or untimely patient recruitment for clinical trials may have serious consequences.&nbsp;&nbsp; The length of the study may be extended, leading to increased costs and staffing concerns.&nbsp;&nbsp; Trials that do not recruit the required number of patients may impact the data integrity.&nbsp; Study teams that cannot recruit patients may not be invited to participate in future studies by industry partners or may have difficulty securing future grants.&nbsp;&nbsp; In some cases, a trial may have to be terminated resulting in unpublishable results, poor financial outcomes, and disappointed stakeholders.<\/p>\n\n\n\n<!--more-->\n\n\n\n<p><a href=\"https:\/\/mhealthfairview.org\/\" target=\"_blank\" rel=\"noreferrer noopener\">M Health Fairview<\/a> is a large healthcare system in Minnesota.&nbsp; M Health Fairview is a joint clinical enterprise involving the University of Minnesota and the Fairview Health Services.&nbsp; M Health includes 10 hospitals, 50 clinics, 5,000 providers and 34,000 employees.&nbsp;&nbsp; M Health values medical research throughout the joint clinical enterprise.&nbsp; In support of research programs, M Health instituted a centralized research recruitment department in 2020.&nbsp; The Fairview Research Recruitment Service (FRRS) was designed to support research teams in the M Health Fairview system.&nbsp;&nbsp; FRRS is actively recruiting clinic patients and hospital inpatients for many types of academic and industry sponsored clinical trials.&nbsp;<\/p>\n\n\n\n<p>The Fairview Research Recruitment Services division is excited to work with academic and community Investigators on clinic-based outpatient research projects.&nbsp; FRRS has historically used IRB-approved US postal recruitment letters to reach out to clinic patients.&nbsp;&nbsp; This method of research recruitment has been reliable for decades.&nbsp; Early in 2021, FRRS began working with the Epic medical record team to deploy the Epic MyChart research recruitment module.&nbsp;&nbsp; Epic MyChart has the ability to send IRB approved research recruitment messages to patients with an active MyChart account.&nbsp; Epic MyChart recruiting has the ability to identify highly qualified patients and electronically communicate with them directly using the MyChart patient Inbasket system.&nbsp;<\/p>\n\n\n\n<p>Researchers throughout the M Health system have been excited about the potential for MyChart to enhance recruitment plans.&nbsp;&nbsp; Since deploying the MyChart recruitment module, FRRS has been collecting recruitment data on both US postal letters and MyChart messaging results.&nbsp; The purpose of this article is to share the early data on MyChart messaging recruitment as compared to US postal letters.<\/p>\n\n\n\n<p>FRRS records all MyChart messages and US postal letters sent to patients.&nbsp; Data has been collected in 2021 for 10 clinical trials.&nbsp; The trials may have used US postal letters, MyChart recruitment messaging or both communication modalities.&nbsp; The involved projects were recruiting patients with various medical histories, including cardiac conditions, orthopedic concerns, HIV and diabetes.&nbsp;&nbsp; This brief examination includes 6,305 US postal letters and 14,700 MyChart messages sent to qualified Fairview clinic patients.&nbsp;&nbsp; The following table demonstrates the effectiveness of both US postal letters and MyChart messages.&nbsp;<\/p>\n\n\n\n<p>Table 1:&nbsp; US Postal Letters and EPIC MyChart Message Results&nbsp; &#8211; Outpatient Clinic Studies<\/p>\n\n\n\n<figure class=\"wp-block-table is-style-regular\"><table><tbody><tr><td><strong>Trial Description<\/strong><\/td><td><strong>US Postal Letters<\/strong><\/td><td><strong>EPIC MyChart Messages<\/strong><\/td><\/tr><tr><td>&nbsp;<\/td><td>Population<\/td><td>Letters Sent<\/td><td>*Patient Response<\/td><td>Response Rate<\/td><td>MyChart Messages<\/td><td>*Patient Response<\/td><td>Response Rate<\/td><\/tr><tr><td>HIV<\/td><td>167<\/td><td>38<\/td><td>23%<\/td><td>198<\/td><td>44<\/td><td>22%<\/td><\/tr><tr><td>HTN<\/td><td>&nbsp;<\/td><td>&nbsp;<\/td><td>&nbsp;<\/td><td>5,931<\/td><td>488<\/td><td>8%<\/td><\/tr><tr><td>CVD<\/td><td>1,570<\/td><td>193<\/td><td>12%<\/td><td>298<\/td><td>36<\/td><td>12%<\/td><\/tr><tr><td>T2DM<\/td><td>1,632<\/td><td>118<\/td><td>7%<\/td><td>507<\/td><td>58<\/td><td>11%<\/td><\/tr><tr><td>CAD<\/td><td>1,680<\/td><td>106<\/td><td>6%<\/td><td>&nbsp;<\/td><td>&nbsp;<\/td><td>&nbsp;<\/td><\/tr><tr><td>A Fib<\/td><td>&nbsp;<\/td><td>&nbsp;<\/td><td>&nbsp;<\/td><td>4,307<\/td><td>333<\/td><td>8%<\/td><\/tr><tr><td>Knee<\/td><td>502<\/td><td>19<\/td><td>4%<\/td><td>1,257<\/td><td>81<\/td><td>6%<\/td><\/tr><tr><td>HFpEF<\/td><td>651<\/td><td>60<\/td><td>9%<\/td><td>&nbsp;<\/td><td>&nbsp;<\/td><td>&nbsp;<\/td><\/tr><tr><td>A Fib<\/td><td>&nbsp;<\/td><td>&nbsp;<\/td><td>&nbsp;<\/td><td>2,202<\/td><td>2374<\/td><td>11%<\/td><\/tr><tr><td><strong>Total<\/strong><\/td><td><\/td><td><strong>6,305<\/strong><\/td><td><strong>534<\/strong><\/td><td><strong>8%<\/strong><\/td><td><strong>14,700<\/strong><\/td><td><strong>1,277<\/strong><\/td><td><strong>9%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>*Patient Response indicates the number of patients that communicated with the study team following receipt of the US postal letter or the MyChart message.&nbsp;<\/p>\n\n\n\n<p>The effectiveness of US Postal letters as compared to MyChart messages is measured by the number of patients that respond to either communication modality.&nbsp;&nbsp; Patients that reach out to the study team as instructed by their recruitment communication represents a positive recruitment endpoint.&nbsp; These patients may result in an enrolled study patient, a study screen failure, a pre-screen termination, a disinterested patient, etc. &nbsp;&nbsp;Regardless, the initial patient response to the study team represents the first step in qualifying, consenting and forming a research relationship with patients.<\/p>\n\n\n\n<p>The studies in Table 1 indicate that the effectiveness of US postal letters and MyChart messages is nearly identical.&nbsp; The study team (or FRRS) received 534 patient responses after mailing 6,305 US postal letters.&nbsp; After sending 14,700 MyChart messages the study team (or FRRS) received a phone call, e-mail or Inbasket reply from 1,277 patients.&nbsp; The results equate to a response rate of 8% and 9% respectively.&nbsp;&nbsp; In the end, both communication modalities adhere to the historical axiom of expecting a patient response rate of 8-10%.&nbsp;<\/p>\n\n\n\n<p>A demographic review of responding patients did not identify any strong correlations.&nbsp; The age difference between respondents is only marginally different, with MyChart responders skewing only slightly younger.<\/p>\n\n\n\n<p><strong>Conclusion:<\/strong><\/p>\n\n\n\n<p>US postal letters and EPIC MyChart messages are effective research recruitment tools.&nbsp; These communication tools provide research teams the ability to identify qualified patients in the Epic medical record system and share IRB approved research recruitment content.&nbsp;&nbsp; Both tools demonstrate a patient response effectiveness rate of 8-9%.&nbsp;&nbsp; Conversations with patients provides further validation of these results.&nbsp; &nbsp;An individual patient may respond to a letter received in the mail, or they may not open their mail for several months.&nbsp;&nbsp; Other patients may open their MyChart message in real-time or delete the message before reading.&nbsp; Neither communication tool is superior.&nbsp;<\/p>\n\n\n\n<p>Research teams are encouraged to consider a joint recruitment strategy that includes both US postal letters and MyChart messages.&nbsp;&nbsp; In order to engage the greatest number of patients a research team can utilize an enhanced laddered strategy that includes both US postal letters and MyChart messaging.&nbsp;&nbsp; Patients may need to hear about a study in several instances before deciding to pursue potential trial participation.<\/p>\n\n\n\n<p>A positive case study example includes an investigational medication trial for patients with type 2 diabetes.&nbsp;&nbsp; This study was initiated with a letter campaign that involved mailing approximately 50 letters each week.&nbsp;&nbsp; The response rate with the US postal letter strategy is 7%.&nbsp;&nbsp; The study team determined that the patient response rate was insufficient to meet their project enrollment goals.&nbsp; FRRS began sending patients the IRB approved MyChart recruitment message 2-3 weeks after their initial letter was mailed.&nbsp;&nbsp;&nbsp; Patients received both a US postal letter and a MyChart message 2-3 weeks apart. The MyChart messages have resulted in an additive response rate of 11%.&nbsp; FRRS conducted a phone prescreen with 58 patients who received a US postal recruitment letter but did not call until having also received the MyChart message.&nbsp;&nbsp; The synergistic effect of utilizing both US postal letters and MyChart messages is resulting in a significantly improved research recruitment, busy coordinators, and a happy Clinical Investigator.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Andrew Snyder MBA, PMP, FACMPE One of the most common challenges of conducting clinical trials is related to problems with recruitment.&nbsp;&nbsp; Insufficient or untimely patient recruitment for clinical trials may have serious consequences.&nbsp;&nbsp; The length of the study may be extended, leading to increased costs and staffing concerns.&nbsp;&nbsp; Trials that do not recruit the required &hellip; <\/p>\n<p><a href=\"https:\/\/www.socra.org\/blog\/research-recruitment-study-mychart-message-recruitment\/\" class=\"more-link\">Continue reading <span class=\"screen-reader-text\">Research Recruitment Study \u2013 MyChart Message Recruitment<\/span> &rarr;<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0},"categories":[5,136,110,67,85],"tags":[135,137,134,116,115],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v15.6.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Research Recruitment Study \u2013 MyChart Message Recruitment - SOCRA Blog<\/title>\n<meta name=\"description\" content=\"The limitations for recruiting in clinical trials and early data on MyChart messaging recruitment as compared to US postal letters.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.socra.org\/blog\/research-recruitment-study-mychart-message-recruitment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Research Recruitment Study \u2013 MyChart Message Recruitment - SOCRA Blog\" \/>\n<meta property=\"og:description\" content=\"The limitations for recruiting in clinical trials and early data on MyChart messaging recruitment as compared to US postal letters.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.socra.org\/blog\/research-recruitment-study-mychart-message-recruitment\/\" \/>\n<meta property=\"og:site_name\" content=\"SOCRA Blog\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SoCRA.org\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-14T18:42:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-10-04T16:06:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.socra.org\/blog\/wp-content\/uploads\/2022\/02\/Snyder-Andrew-683x1024.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@socranow\" \/>\n<meta name=\"twitter:site\" content=\"@socranow\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\">\n\t<meta name=\"twitter:data1\" content=\"6 minutes\">\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.socra.org\/blog\/#website\",\"url\":\"https:\/\/www.socra.org\/blog\/\",\"name\":\"SOCRA Blog\",\"description\":\"Educational Content Supporting Clinical Research Excellence\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":\"https:\/\/www.socra.org\/blog\/?s={search_term_string}\",\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/www.socra.org\/blog\/research-recruitment-study-mychart-message-recruitment\/#primaryimage\",\"inLanguage\":\"en-US\",\"url\":\"https:\/\/www.socra.org\/blog\/wp-content\/uploads\/2022\/02\/Snyder-Andrew-683x1024.jpg\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.socra.org\/blog\/research-recruitment-study-mychart-message-recruitment\/#webpage\",\"url\":\"https:\/\/www.socra.org\/blog\/research-recruitment-study-mychart-message-recruitment\/\",\"name\":\"Research Recruitment Study \\u2013 MyChart Message Recruitment - SOCRA Blog\",\"isPartOf\":{\"@id\":\"https:\/\/www.socra.org\/blog\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.socra.org\/blog\/research-recruitment-study-mychart-message-recruitment\/#primaryimage\"},\"datePublished\":\"2022-02-14T18:42:25+00:00\",\"dateModified\":\"2022-10-04T16:06:14+00:00\",\"author\":{\"@id\":\"https:\/\/www.socra.org\/blog\/#\/schema\/person\/54fcc368d0177213a922b9fc813212dd\"},\"description\":\"The limitations for recruiting in clinical trials and early data on MyChart messaging recruitment as compared to US postal letters.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.socra.org\/blog\/research-recruitment-study-mychart-message-recruitment\/\"]}]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.socra.org\/blog\/#\/schema\/person\/54fcc368d0177213a922b9fc813212dd\",\"name\":\"SOCRA\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/www.socra.org\/blog\/#personlogo\",\"inLanguage\":\"en-US\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f79e358717b94d833d65e6d6c2e5d07e?s=96&d=mm&r=g\",\"caption\":\"SOCRA\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","_links":{"self":[{"href":"https:\/\/www.socra.org\/blog\/wp-json\/wp\/v2\/posts\/584"}],"collection":[{"href":"https:\/\/www.socra.org\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.socra.org\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.socra.org\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.socra.org\/blog\/wp-json\/wp\/v2\/comments?post=584"}],"version-history":[{"count":6,"href":"https:\/\/www.socra.org\/blog\/wp-json\/wp\/v2\/posts\/584\/revisions"}],"predecessor-version":[{"id":599,"href":"https:\/\/www.socra.org\/blog\/wp-json\/wp\/v2\/posts\/584\/revisions\/599"}],"wp:attachment":[{"href":"https:\/\/www.socra.org\/blog\/wp-json\/wp\/v2\/media?parent=584"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.socra.org\/blog\/wp-json\/wp\/v2\/categories?post=584"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.socra.org\/blog\/wp-json\/wp\/v2\/tags?post=584"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}